Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma.

Ghobrial IM, Munshi NC, Harris BN, Shi P, Porter NM, Schlossman RL, Laubach JP, Anderson KC, Desaiah D, Myrand SP, Wooldridge JE, Richardson PG, Abonour R. A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma. Am J Hematol. 2011 Jul; 86(7):573-8.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.